Sep 30, 2025 10:35 AM Eastern Daylight Time Share FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Novo To Contact Him Directly To Discuss Their Options If you suffered losses in Novo between May 7, 2025, to July 28, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983- ...

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Rezolve AI plc due to allegations of materially misleading business information issued by the company [1] Group 1 - The investigation is focused on the potential impact of misleading information on investors [1] - Shareholders who purchased Rezolve securities may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]

Core Viewpoint - A lawsuit has been filed against Lineage, Inc. and its senior executives for potential violations of federal securities laws related to its IPO and subsequent financial performance [1][2]. Group 1: Lawsuit Details - Investors have until September 30, 2025, to request to lead the case, which is based on claims under Sections 11 and 15 of the Securities Act of 1933 [2]. - The lawsuit is pending in the U.S. District Court for the Eastern District of Michigan, specifically titled City of St. Clair Shores Police and Fire Retirement System v. Lineage, Inc., et al. [2]. Group 2: Company Overview - Lineage, Inc. operates as a cold storage-focused real estate investment trust (REIT), owning and managing temperature-controlled storage facilities for perishable products [3]. Group 3: Allegations and Financial Performance - The IPO documents claimed strong cash flows due to consistent cold chain demand, suggesting resilience during economic stress, while the reality indicated a downturn as customers destocked excess inventory from the pandemic [4]. - Following the IPO at $78 per share, Lineage's stock price has significantly declined to around $40 per share, approximately 50% of its initial value [5].

NEW YORK--(BUSINESS WIRE)---- $SOC #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Sable Offshore Corp. ("Sable Offshore†or the "Company†) (NYSE: SOC) and reminds investors of the September 26, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgi ...

NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of Cytokinetics, Inc. (NASDAQ: CYTK) between December 27, 2023 and May 6, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 17, 2025. SO WHAT: If you purchased Cytokinetics common stock duri ...

Core Viewpoint - Rosen Law Firm is reminding investors of KinderCare Learning Companies, Inc. about the upcoming lead plaintiff deadline for a class action lawsuit related to the company's October 2024 IPO [1]. Group 1: Class Action Details - Investors who purchased KinderCare common stock may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by October 14, 2025 [3]. - The lawsuit claims that the registration statement was false and/or misleading, failing to disclose incidents of child abuse and neglect at KinderCare facilities, and that the company did not meet minimum care standards [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. due to allegations of materially misleading business information [1] Group 1: Company Information - Tandem Diabetes Care issued a press release on August 7, 2025, regarding a voluntary medical device correction for select t:slim X2 insulin pumps, addressing a potential speaker-related issue that could lead to insulin delivery discontinuation [3] - Following the announcement, Tandem Diabetes' stock experienced a significant decline of 19.9% on the same day [3] Group 2: Legal Actions - Rosen Law Firm is preparing a class action lawsuit to seek recovery of investor losses for those who purchased Tandem Diabetes Care securities, with no out-of-pocket fees for participants through a contingency fee arrangement [2] - Investors interested in joining the class action can submit their information through the Rosen Law Firm's website or contact them directly [2] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and consistently ranking in the top 4 for securities class action settlements since 2013 [4] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for its clients [4]

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of V.F. Corporation securities between October 30, 2023, and May 20, 2025, alleging that the company disseminated materially false and misleading statements regarding its turnaround plans [1][5]. Group 1: Lawsuit Details - The lawsuit claims that V.F. Corporation concealed significant reset actions necessary for the Vans brand to return to growth, which negatively impacted revenue growth [5]. - Investors who purchased V.F. Corporation securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - A lead plaintiff must move the Court by November 12, 2025, to represent other class members in the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including over $438 million for investors in 2019 [4]. - The firm has been recognized for its success in securities class action settlements, ranking in the top 4 since 2013 [4].

Core Viewpoint - A class action lawsuit has been filed against Quanex Building Products Corporation for failing to disclose significant operational issues related to its Tyman acquisition, which has led to a substantial decline in stock price following the revelation of these issues [1][2][3]. Group 1: Allegations and Issues - The lawsuit alleges that Quanex's maintenance procedures and policies at its Tyman Mexico facility were significantly underinvested, leading to degraded tooling and equipment conditions [2]. - It is claimed that the company was likely to incur significant costs due to these operational issues, which would delay the expected benefits from the Tyman integration [2]. - The complaint states that Quanex had previously identified these issues but failed to disclose them, resulting in misleading positive statements about the company's business and prospects [2]. Group 2: Stock Price Impact - Following the revelation of the operational issues, Quanex's stock price fell by $2.73, or 13.1%, closing at $18.18 per share on September 5, 2025 [3]. - The stock continued to decline, dropping an additional $1.98, or 10.9%, to close at $16.20 per share on September 8, 2025 [3].

Core Viewpoint - C3.ai, Inc. is facing a class action lawsuit due to allegations of misleading statements regarding its growth and the impact of its CEO's health on the company's performance, leading to a significant drop in stock price following disappointing financial results [1][2]. Summary by Relevant Sections Allegations - The complaint claims that C3.ai's management provided overly positive statements while concealing material adverse facts about the company's growth, particularly the CEO's health affecting deal closures and overall performance [1]. - The company announced disappointing preliminary financial results for Q1 of fiscal 2026 and reduced its revenue guidance for the full fiscal year 2026, attributing these issues to "the reorganization with new leadership" and the CEO's health problems [1]. Stock Price Impact - Following the announcement on August 8, 2025, C3.ai's stock price fell from $22.13 per share to $16.47 per share by August 11, 2025, marking a decline of approximately 25.58% in just one day [1]. Class Action Details - Shareholders who purchased shares during the class period from February 26, 2025, to August 8, 2025, are encouraged to register for the class action, with a deadline for lead plaintiff appointment set for October 21, 2025 [2]. - Participants will be enrolled in a portfolio monitoring system to receive updates throughout the case lifecycle [2].